CCR5 and ovarian cancer: To ensure that 4H11-CCR2b and 4H11-CCR5 retained cytotoxicity, we cocultured both armored CAR-T cells with either OVCAR3 or SKOV3-Muc16+ ovarian cancer tumor cells for 48 h at effector to target (E:T) ratios of 1:1 and 5:1 (Figure 3C).